Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 8, 2010, Pages 1742-1748

  Kaur, Jaspreet ^a   Sundar, Shyam ^b   Singh, Neeloo ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Antileishmanial agents; Flow cytometry; Green fluorescent protein

Indexed keywords

DIHYDROPTERIDINE REDUCTASE INIBITOR; ENZYME INHIBITOR; MONASTROL; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; OXIDOREDUCTASE; PTERIDINE REDUCTASE; PYRIMIDINE DERIVATIVE; THIOKETONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG POTENCY; ENANTIOMER; ENZYME ACTIVE SITE; ENZYME INHIBITION; IC 50; LEISHMANIA DONOVANI; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; VISCERAL LEISHMANIASIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SENSITIVITY; HAMSTER; IC50; ISOLATION AND PURIFICATION; LEISHMANIASIS, VISCERAL; MACROPHAGE; MESOCRICETUS; MOLECULAR DYNAMICS; ORAL DRUG ADMINISTRATION; PARASITOLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; MESOCRICETUS; MOLECULAR DYNAMICS SIMULATION; OXIDOREDUCTASES; PARASITIC SENSITIVITY TESTS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIONES;

EID: 77954715638     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq189     Document Type: Article

References (32)

1. Thakur CP, Kumar A, Thakur M et al. Newer strategies for the kala-azar elimination programme in India. Indian J Med Res 2009; 129: 102-4.
2. Smith DF, Peacock CS, Cruz AK. Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int J Parasitol 2007; 37: 1173-86.
3. Wilson ME, Jeronimo SM, Pearson RD. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 2005; 38: 147-60.
4. Sundar S, Jha TK, Thakur CP. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356: 2571-81.
5. Singh N. New drug targets in Leishmania. In: Raghunath D, Nayak R, eds, Trends and Research in Leishmaniasis with Particular Reference to Kala azar. Sir Dorabji Tata Symposium Series 2005; 5: 343-63.
6. Kumar P, Kumar A, Verma SS et al. Leishmania donovani pteridine reductase 1: biochemical properties and structure modeling studies. Exp Parasitol 2008; 120:73-9.
7. Kappe CO. Biologically active dihydropyrimidones of the Biginelli-type, a literature survey. Eur J Med Chem 2000; 35: 1043-52.
8. Kappe CO. 100 Years of the Biginelli dihydropyridine synthesis. 6. Tetrahedron 1993; 49: 6937.
9. Kaur J, Singh BK, Tripathi RP et al. Leishmania donovani: a glycosyl dihydropyridine analogue induces apoptosis like cell death via targeting pteridine reductase 1 in promastigotes. Exp Parasitol 2009; 123: 258-64.
10. Singh N, Kaur J, Kumar P et al. An orally effective dihydropyrimidone (DHPM) analogue induces apoptosis-like cell death in clinical isolates of Leishmania donovani overexpressing pteridine reductase 1. Parasitol Res 2009; 105: 1317-25.
11. Kaur J, Singh N, Singh BK et al. Leishmania donovani: oral therapy with glycosyl 1, 4-dihydropyridine analogue showing apoptosis like phenotypes targeting pteridine reductase 1 in intracellular amastigotes. Exp Parasitol 2010; 125: 310-4.
12. Mayer TU, Kapoor TM, Haggarty SJ et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999; 286: 971-4.
13. Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature 2009; 462: 175-81.
14. Yoshiaki K. Nanoparticulate systems for improved drug delivery. Adv Drug Deliv Rev 2001; 47:1-2.
15. Singh N. Is there true Sb (V) resistance in Indian kala-azar field isolates? Curr Sci 2002; 83: 101-2.
16. Singh N, Dube A. Fluorescent Leishmania: application to antileishmanial drug testing. Am J Trop Med Hyg 2004; 71: 400-2.
17. Sali A, Blundell TL. Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
18. Gourley DG, Schüttelkopf AW, Leonard GA et al. Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites. Nat Struct Biol 2001; 8: 521-5.
19. Ghadirian E, Meerovitch E. Effect of splenectomy on the size of amoebic liver abscesses and metastatic foci in hamsters. Infect Immun 1981; 31: 571-3.
20. Murray HW, Lu CM, Mauze S et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002; 70: 6284-93.
21. Manandhar KD, Yadav TP, Prajapati VK et al. Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother 2008; 62: 376-80.
22. Kumar P, Kothari H, Singh N. Overexpression in Escherichia coli and purification of pteridine reductase 1 (PTR1) from a clinical isolate of Leishmania donovani. Protein Expr Purif 2004; 38: 228-36.
23. Bello AR, Nare B, Freedman D et al. PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major. Proc Natl Acad Sci USA 1994; 91: 11442-6.
24. Kapoor TM, Mayer TU, Coughlin ML et al. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000; 150: 975-88.
25. Roth BL, Sheffler DJ, Kroeze WK et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3: 353-9.
26. Maliga Z, Mitchison TJ. Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Chem Biol 2006; 6:2.
27. Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in kala azar field isolates. J Infect Dis 2003; 188: 600-7.
28. Atwal KS, Swanson BN, Unger SE et al. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidine carboxylic acid esters as orally effective antihypertensive agents. J Med Chem 1991; 34: 806-11.
29. Hardy LW, Matthews W, Nare B et al. Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways. Exp Parasitol 1997; 87: 157-69.
30. Patil AD, Kumar NV, Kokke WC et al. Novel alkaloids from the sponge Batzella sp.: inhibitors of HIV gp120-human CD4 binding. J Org Chem 1995; 60: 1182-8.
31. Shallom S, Zhang K, Jiang L et al. Essential protein-protein interactions between Plasmodium falciparum thymidylate synthase and dihydrofolate reductase domains. J Biol Chem 1999; 274: 37781-6.
32. Cavazzuti A, Paglietti G, Hunter WN et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc Natl Acad Sci USA 2008; 105: 1448-53.